Nanomaterials,
Journal Year:
2024,
Volume and Issue:
14(21), P. 1760 - 1760
Published: Nov. 1, 2024
Psoriasis
and
breast
cancer
are
two
examples
of
diseases
where
associated
inflammatory
pathways
within
the
body's
immune
system
implicated.
is
a
complex,
chronic
incurable
skin
disorder
that
primarily
recognized
by
thick,
scaly
plaques
on
skin.
The
most
noticeable
pathophysiological
effect
psoriasis
abnormal
proliferation
keratinocytes.
Breast
currently
diagnosed
leading
cause
cancer-related
death
among
women
globally.
While
treatments
targeting
primary
tumor
have
significantly
improved,
preventing
metastasis
with
systemic
less
effective.
Nanocarriers
such
as
liposomes
lipid
nanoparticles
emerged
promising
drug
delivery
systems
for
specificity.
Advances
in
technologies
combinations
to
develop
more
efficient
nanocarriers
include
than
one
combinational
therapy
enhance
treatment
outcomes
and/or
relief
symptoms
better
patients'
quality
life.
Although
there
FDA-approved
anti-cancer
drugs
cancer,
still
unmet
clinical
needs
reduce
side
effects
those
nanomedicines.
Hence,
nano-therapy
may
eliminate
some
issues
challenges.
Furthermore,
no
nanomedicines
yet
clinically
available
psoriasis.
this
review
will
focus
encapsulated
single
augment
an
emphasis
effectiveness
liposomal-based
nanoparticulate
tackle
cancer.
This
also
overview
both
diseases,
challenges
delivering
roles
well
models
used
testing
therapeutic
interventions
pave
way
effective
vivo
prior
trials.
Medicine in Drug Discovery,
Journal Year:
2024,
Volume and Issue:
22, P. 100183 - 100183
Published: March 8, 2024
Psoriasis
is
a
chronic
autoimmune
disorder
that
has
major
effect
on
the
quality
of
life
for
millions
people
throughout
world.
The
pathogenesis
psoriasis
revealed
intricate
molecular
networks
and
signaling
pathways,
opening
new
avenues
precision
medicine.
treatments
include
topical
therapy,
phototherapy,
systemic
therapies,
biologics,
but
achieving
optimal
outcomes
difficult.
Despite
advancements
in
understanding
causes
development
various
treatments,
optimizing
therapeutic
remains
challenging.
Managing
poses
challenges
terms
drug
delivery
evaluation
models.
Novel
systems
capable
navigating
complex
skin
barriers
delivering
therapeutics
precisely
to
target
cells
are
crucial
advancing
treatment
options.
This
article
provides
an
inclusive
overview
psoriasis,
highlighting
recent
discoveries
potential
targets.
emphasizes
importance
combining
different
modalities,
such
as
synthetic
herbal
agents,
with
biologics
improve
efficacy.
Nanocarriers
show
promise
targeted
they
can
encapsulate
antipsoriatic
drugs,
gene
providing
enhanced
stability,
improved
tissue
penetration,
precise
cellular
targeting.
These
have
revolutionize
by
maximizing
efficacy
while
minimizing
side
effects.
also
discusses
commercial
formulations,
including
patents
related
ongoing
clinical
trials,
which
provide
valuable
insights
into
evolving
landscape
therapeutics.
provided
contribute
field
offer
hope
patients
suffering
from
psoriasis.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(2), P. 678 - 678
Published: Feb. 17, 2023
Orally
administered
antipsychotic
drugs
are
the
first-line
treatment
for
psychotic
disorders,
such
as
schizophrenia
and
bipolar
disorder.
Nevertheless,
adverse
drug
reactions
jeopardize
clinical
outcomes,
resulting
in
patient
non-compliance.
The
design
formulation
strategies
enhancing
brain
delivery
has
been
a
major
challenge,
mainly
due
to
restrictive
properties
of
blood-brain
barrier.
However,
recent
pharmacokinetic
pharmacodynamic
vivo
assays
confirmed
advantage
intranasal
route
when
compared
oral
intravenous
administration,
it
allows
direct
nose-to-brain
transport
via
neuronal
pathways,
reducing
systemic
side
effects
maximizing
therapeutic
outcomes.
In
addition,
incorporation
into
nanosystems
polymeric
nanoparticles,
mixed
micelles,
solid
lipid
nanostructured
carriers,
nanoemulsions,
nanoemulgels,
nanosuspensions,
niosomes
spanlastics,
proven
be
quite
promising.
developed
nanosystems,
having
small
homogeneous
particle
size
(ideal
delivery),
high
encapsulation
efficiency
good
stability,
resulted
improved
bioavailability
therapeutic-like
animal
models.
Hence,
although
is
essential
continue
research
this
field,
schizophrenia,
disorder
other
related
disorders
promising,
opening
path
future
therapies
with
higher
efficacy.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(5), P. 651 - 651
Published: May 11, 2024
Myasthenia
gravis
(MG)
is
a
rare
chronic
autoimmune
disease
caused
by
the
production
of
autoantibodies
against
postsynaptic
membrane
receptors
present
at
neuromuscular
junction.
This
condition
characterized
fatigue
and
muscle
weakness,
including
diplopia,
ptosis,
systemic
impairment.
Emerging
evidence
suggests
that
in
addition
to
immune
dysregulation,
pathogenesis
MG
may
involve
mitochondrial
damage
ferroptosis.
Mitochondria
are
primary
site
energy
production,
reactive
oxygen
species
(ROS)
generated
due
dysfunction
can
induce
Nanomedicines
have
been
extensively
employed
treat
various
disorders
their
modifiability
good
biocompatibility,
but
application
management
has
rather
limited.
Nevertheless,
nanodrug
delivery
systems
carry
immunomodulatory
agents,
anti-oxidants,
or
ferroptosis
inhibitors
could
be
effective
for
treatment
MG.
Therefore,
this
review
focuses
on
nanoplatforms
aimed
attenuating
restoring
function,
inhibiting
potentially
serve
as
promising
agents
targeted
therapy.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(2), P. 468 - 468
Published: Jan. 31, 2023
Melasma
is
a
hard-to-treat
hyperpigmentation
disorder.
Combined
incorporation
of
kojic
dipalmitate
(KDP),
the
esterified
form
acid,
and
rosehip
oil,
an
oil
with
antioxidant
skin-regenerating
properties,
into
nanocarrier
systems
appears
to
be
suitable
strategy
develop
high-performance
formulations.
A
high-energy
method
(Ultra-Turrax®)
was
used
nanoemulsions
containing
up
2
mg/mL
KDP,
5%
7.5%
surfactant.
Formulations
were
characterized
regarding
droplet
size,
size
distribution,
pH,
density,
morphology,
KDP
content,
efficiency,
stability
under
different
temperature
conditions.
scale-up
study
conducted.
Skin
permeation,
potential,
tyrosinase
inhibitory
activity
assessed
in
vitro.
Cell
viability
studies
also
performed.
Results
showed
that
1
had
efficiencies
greater
than
95%,
smaller
130
nm,
zeta
potential
approximately
-10
mV,
good
over
30
days
refrigerated
storage.
The
nanoemulsion
chosen
for
further
evaluation
because
it
lower
nanocrystal
formation,
feasibility
allowed
permeation
epidermis
similarly
observed
KDP.
This
formulation
(1
KDP)
depigmenting
efficacy,
close
mM
ascorbic
acid.
No
cytotoxicity
formulations
concentrations
ranging
from
0.06%
1%.
